These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 1810452)
21. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells. Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813 [TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of living BCG or BCG cell walls (CW) in the treatment of guinea pig hepatoma. Zbar B; Hunter J; Rapp HJ; Canti G Cancer; 1979 Feb; 43(2):484-91. PubMed ID: 421175 [TBL] [Abstract][Full Text] [Related]
24. Histologic and ultrastructural studies of tumor regression in inbred guinea pigs after intralesional injection of Mycobacterium bovis (BCG). Hanna MG; Snodgrass MJ; Zbar B; Rapp HJ Natl Cancer Inst Monogr; 1973 Dec; 39():71-85. PubMed ID: 4362524 [No Abstract] [Full Text] [Related]
25. Immunotherapy of the guinea pig line 10 hepatocarcinoma with a variety of nonviable bacteria. Brunda MJ; Mathews HL; Ferguson HR; McClatchy JK; Minden P Cancer Res; 1980 Sep; 40(9):3211-3. PubMed ID: 6775802 [TBL] [Abstract][Full Text] [Related]
26. Failure of cryosurgical treatment of experimental intradermal tumors to eradicate microscopic lymph node metastases in guinea pigs. Javadpour N; Bagley DH; Zbar B J Natl Cancer Inst; 1979 Jun; 62(6):1479-81. PubMed ID: 286120 [TBL] [Abstract][Full Text] [Related]
27. Immunotherapy by intralesional injection of BCG cell walls or live BCG in bovine ocular squamous cell carcinoma: a preliminary report. Klein WR; Ruitenberg EJ; Steerenberg PA; de Jong WH; Kruizinga W; Misdorp W; Bier J; Tiesjema RH; Kreeftenberg JG; Teppema JS; Rapp HJ J Natl Cancer Inst; 1982 Nov; 69(5):1095-103. PubMed ID: 6957655 [TBL] [Abstract][Full Text] [Related]
28. Enhanced immunogenicity of line 10 guinea pig hepatocarcinoma cells after culture. Correll LL; Nielsen LD; Kelleher PJ; Harbell JW; Minden P J Natl Cancer Inst; 1983 Dec; 71(6):1343-6. PubMed ID: 6581367 [TBL] [Abstract][Full Text] [Related]
29. Histological evaluation of immunologically mediated tumor regression of the line 10 guinea pig hepatocarcinoma. de Jong WH; Teppema JS; Wagenaar SS; Paques M; Steerenberg PA; Ruitenberg EJ Virchows Arch B Cell Pathol Incl Mol Pathol; 1986; 50(3):249-69. PubMed ID: 2870577 [TBL] [Abstract][Full Text] [Related]
30. Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery. Hanna MG; Peters LC Cancer; 1978 Dec; 42(6):2613-25. PubMed ID: 728864 [TBL] [Abstract][Full Text] [Related]
31. Recombinant interleukin-12 and interleukin-18 antitumor therapy in a guinea-pig hepatoma cell implant model. Shiratori I; Suzuki Y; Oshiumi H; Begum NA; Ebihara T; Matsumoto M; Hazeki K; Kodama K; Kashiwazaki Y; Seya T Cancer Sci; 2007 Dec; 98(12):1936-42. PubMed ID: 17888032 [TBL] [Abstract][Full Text] [Related]
32. Synergistic activity of components of mycobacteria and mutant Salmonella in causing regression of line-10 tumors in guinea pigs. McLaughlin CA; Hargrave SL; Bickel WD; Ribi E Cancer Res; 1979 May; 39(5):1766-71. PubMed ID: 371795 [No Abstract] [Full Text] [Related]
34. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768 [TBL] [Abstract][Full Text] [Related]
35. Postoperative active-specific immunotherapy of lymph node micrometastasis in a guinea pig tumor model. Bier H; Armonat G; Bier J; Schirrmacher V; Ganzer U ORL J Otorhinolaryngol Relat Spec; 1989; 51(4):197-205. PubMed ID: 2664632 [TBL] [Abstract][Full Text] [Related]
36. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242 [TBL] [Abstract][Full Text] [Related]
37. Modulation of cell-mediated alloimmunity by BCG. I. Antagonism and potentiation of immunosuppression caused by cytarabine. Murahata RI; Mitchell MS J Natl Cancer Inst; 1982 Sep; 69(3):607-12. PubMed ID: 6981020 [TBL] [Abstract][Full Text] [Related]
38. Active specific immunotherapy of residual micrometastasis: the acute and chronic inflammatory response in induction of tumor immunity by BCG-tumor cell immunization. Hanna MG; Bucana C J Reticuloendothel Soc; 1979 Oct; 26(4):439-51. PubMed ID: 513055 [No Abstract] [Full Text] [Related]
39. Mechanisms of action of intravesical BCG for bladder cancer. Ratliff TL Prog Clin Biol Res; 1989; 310():107-22. PubMed ID: 2672010 [TBL] [Abstract][Full Text] [Related]
40. Current status and potential application of ISCOMs in veterinary medicine. Morein B; Hu KF; Abusugra I Adv Drug Deliv Rev; 2004 Jun; 56(10):1367-82. PubMed ID: 15191787 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]